No Data
No Data
No Data
No Data
No Data
Cstone Pharmaceuticals' CEO Boosts Stakeholding
Cstone Pharmaceuticals' (HKG:2616) CEO Jianxin Yang bought around an additional 3.3 million shares on the market during the six months ended today, Monday, a same-day filing on the Hong Kong bourse sa
MT NewswiresApr 29 18:34
Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%
Cstone Pharmaceuticals (HKG:2616) reported a loss for the year attributable to owners of about 367.2 million yuan, down from a loss of 902.7 yuan in the previous year, according to the annual results
MT NewswiresApr 24 15:57
China Accepts CStone Pharmaceuticals' Manufacturing Application for RET Inhibitor
China's medical products administrator accepted CStone Pharmaceuticals' (HKG:2616) manufacturing localization application for its pralsetinib RET inhibitor, according to a Tuesday filing with the Hong
MT NewswiresApr 9 09:52
Cstone Pharmaceuticals Cancer Drug Gets Supplemental Biologics License Application Approved
Cstone Pharmaceuticals (HKG:2616) said China's National Medical Products Administration (NMPA) approved a supplemental biologics license application (sBLA) for sugemalimab in combination with fluoropy
MT NewswiresMar 15 14:40
CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer
Yahoo FinanceMar 15 12:05
Insider Purchases Worth CN¥6.54m See Losses As CStone Pharmaceuticals Market Value Drops To HK$1.4b
The recent price decline of 31% in CStone Pharmaceuticals' (HKG:2616) stock may have disappointed insiders who bought CN¥6.54m worth of shares at an average price of CN¥2.52 in the past 12 months. In
Simply Wall StMar 5 07:49
No Data
No Data